ID   MCF-7/TAMR-1
AC   CVCL_M436
SY   MCF7/TAMR-1; MCF7 TAMR-1; MCF-7/TAM(R)-1; MCF7-TAMR; TAMR-1; TamR-1; TamR1; AL-1
DR   cancercelllines; CVCL_M436
DR   CancerTools; 152089
DR   ChEMBL-Cells; CHEMBL4513115
DR   Millipore; SCC101
DR   Wikidata; Q54904381
DR   Ximbio; 152089
RX   PubMed=1622627;
RX   PubMed=7664983;
RX   PubMed=16172194;
RX   PubMed=18824559;
RX   PubMed=25362855;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): Millipore
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 14
ST   D21S11: 30
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 8,9
ST   D8S1179: 10,14
ST   FGA: 23,25
ST   Penta D: 12
ST   Penta E: 7,12
ST   TH01: 6
ST   TPOX: 9,12
ST   vWA: 14,15
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1D47 ! MCF-7/S0.5
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 05-10-23; Version: 23
//
RX   PubMed=1622627; DOI=10.3109/02841869209088892;
RA   Lykkesfeldt A.E., Sorensen E.K.;
RT   "Effect of estrogen and antiestrogens on cell proliferation and
RT   synthesis of secreted proteins in the human breast cancer cell line
RT   MCF-7 and a tamoxifen resistant variant subline, AL-1.";
RL   Acta Oncol. 31:131-138(1992).
//
RX   PubMed=7664983; DOI=10.1016/0303-7207(95)03503-Y;
RA   Madsen M.W., Reiter B.E., Lykkesfeldt A.E.;
RT   "Differential expression of estrogen receptor mRNA splice variants in
RT   the tamoxifen resistant human breast cancer cell line, MCF-7/TAMR-1
RT   compared to the parental MCF-7 cell line.";
RL   Mol. Cell. Endocrinol. 109:197-207(1995).
//
RX   PubMed=16172194; DOI=10.1677/erc.1.00946;
RA   Frogne T., Jepsen J.S., Larsen S.S., Fog C.K., Brockdorff B.L.,
RA   Lykkesfeldt A.E.;
RT   "Antiestrogen-resistant human breast cancer cells require activated
RT   protein kinase B/Akt for growth.";
RL   Endocr. Relat. Cancer 12:599-614(2005).
//
RX   PubMed=18824559; DOI=10.1677/ERC-07-0240;
RA   Pancholi S., Lykkesfeldt A.E., Hilmi C., Banerjee S., Leary A.,
RA   Drury S., Johnston S.R.D., Dowsett M., Martin L.-A.;
RT   "ERBB2 influences the subcellular localization of the estrogen
RT   receptor in tamoxifen-resistant MCF-7 cells leading to the activation
RT   of AKT and RPS6KA2.";
RL   Endocr. Relat. Cancer 15:985-1002(2008).
//
RX   PubMed=25362855; DOI=10.1038/onc.2014.351;
RA   Thrane S., Pedersen A.M., Thomsen M.B.H., Kirkegaard T.,
RA   Rasmussen B.B., Duun-Henriksen A.K., Laenkholm A.-V., Bak M.,
RA   Lykkesfeldt A.E., Yde C.W.;
RT   "A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as
RT   novel treatment targets in antiestrogen-resistant breast cancer
RT   cells.";
RL   Oncogene 34:4199-4210(2015).
//